Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification
- PMID: 22015886
- DOI: 10.1097/AOG.0b013e31823403f4
Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification
Abstract
Fetal and neonatal alloimmune thrombocytopenia constitutes the most common cause of severe thrombocytopenia in fetuses and neonates and of intracranial hemorrhage among term newborns. The cornerstone of therapy involves the use of steroids and intravenous immunoglobulins. Despite the risk of potentially devastating consequences to the fetus, fetal blood sampling has typically been used to document response to therapy. We propose a therapeutic algorithm based on risk stratification with individualized treatment optimization without the use of fetal blood sampling.
References
-
- Hohlfeld P, Forestier F, Kaplan C, Tissot JD, Daffos F. Fetal thrombocytopenia: a retrospective study of 5,194 fetal blood samplings. Blood 1994;84:1851–6.
-
- Bussel JB, Zabusky ME, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997;337:22–6.
-
- Mao C, Guo J, Chituwo BM. Intraventricular hemorrhage and it's prognosis, prevention, and treatment in term infants. J Trop Pediatr.1999;45:237–40.
-
- Bussel JB, Zacharoulis S, Kramer K, McFarland JG, Pauliny J, Kaplan C. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005;45:176–83.
-
- Turner M, Bessos H, Fagge T, Harkness M, Rentoul F, Seymour J, et al.. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005;45:1945–56.
MeSH terms
LinkOut - more resources
Full Text Sources
